Skip to main content

ADVERTISEMENT

precision medicine

Research in Review
11/17/2016
JCP Editors
Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to a study published in the Journal of...
Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to a study published in the Journal of...
...
11/17/2016
Journal of Clinical Pathways
Interview
11/15/2016
An interview with Mark Fleury, PhD, MS, principal, Policy Development, Emerging Science, American Cancer Society Cancer Action Network, Washington, DC.  Pain as a result of cancer or cancer treatment...
An interview with Mark Fleury, PhD, MS, principal, Policy Development, Emerging Science, American Cancer Society Cancer Action Network, Washington, DC.  Pain as a result of cancer or cancer treatment...
An...
11/15/2016
Journal of Clinical Pathways
Research in Review
11/15/2016
JCP Editors
A new study has shown that an Enhanced Recovery After Surgery (ERAS) pathway for colorectal surgery can help to reduce complications from health services utilization and significantly reduce total...
A new study has shown that an Enhanced Recovery After Surgery (ERAS) pathway for colorectal surgery can help to reduce complications from health services utilization and significantly reduce total...
A new...
11/15/2016
Journal of Clinical Pathways
Research in Review
11/15/2016
JCP Editors
Targeted therapies have been shown to significantly improve the survival of patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer. However, these therapies have also been associated...
Targeted therapies have been shown to significantly improve the survival of patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancer. However, these therapies have also been associated...
...
11/15/2016
Journal of Clinical Pathways
Research in Review
11/14/2016
JCP Editors
An anti-PD-1 therapy significantly improves overall survival (OS) compared with chemotherapy in previously treated patients with advanced bladder (urothelial) cancer, according to a study presented at the Society for...
An anti-PD-1 therapy significantly improves overall survival (OS) compared with chemotherapy in previously treated patients with advanced bladder (urothelial) cancer, according to a study presented at the Society for...
An...
11/14/2016
Journal of Clinical Pathways
Quiz
11/10/2016
JCP Editors
A study published in JAMA Oncology recently showed that treatment with which of the following drug types was just as effective as BRAF- and MEK-targeted therapies for melanoma and also limited the risk of...
A study published in JAMA Oncology recently showed that treatment with which of the following drug types was just as effective as BRAF- and MEK-targeted therapies for melanoma and also limited the risk of...
A...
11/10/2016
Journal of Clinical Pathways
Research in Review
11/10/2016
JCP Editors
Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors (VEGF), supporting efforts for further research, according...
Tivozanib was well-tolerated and showed promising antitumor activity in patients with soft tissue sarcoma overexpressing vascular endothelial growth factors (VEGF), supporting efforts for further research, according...
...
11/10/2016
Journal of Clinical Pathways
Research in Review
11/09/2016
JCP Editors
According to researchers, characteristics of glioblastoma including seizures, location, and pressure in the brain give valuable insight into length of survival as well as treatment options for patients over the age...
According to researchers, characteristics of glioblastoma including seizures, location, and pressure in the brain give valuable insight into length of survival as well as treatment options for patients over the age...
...
11/09/2016
Journal of Clinical Pathways
Research in Review
11/03/2016
JCP Editors
Most oral antineoplastic drugs approved in the past six years are associated with multiple, clinically significant drug-drug interactions (DDIs). Therefore, the onus remains on oncologists to be more of aware DDIs...
Most oral antineoplastic drugs approved in the past six years are associated with multiple, clinically significant drug-drug interactions (DDIs). Therefore, the onus remains on oncologists to be more of aware DDIs...
Most...
11/03/2016
Journal of Clinical Pathways
10/31/2016
JCP Editors
The neutrophil-to-lymphocyte ratio (NLR) may not be as reliable as previously believed at predicating cancer progression and which drugs will be the most effective, according to results published in Cancer. Risk...
The neutrophil-to-lymphocyte ratio (NLR) may not be as reliable as previously believed at predicating cancer progression and which drugs will be the most effective, according to results published in Cancer. Risk...
The...
10/31/2016
Journal of Clinical Pathways